Display Settings:

Format

Send to:

Choose Destination
    Vaccine. 2009 Aug 21;27 Suppl 3:C3-5. Epub 2009 Jun 23.

    New insights on pneumococcal disease: what we have learned over the past decade.

    Source

    Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 151, Beer-Sheva 84101, Israel. rdagan@bgu.ac.il

    Abstract

    Since the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2000, significant reductions in the rate of invasive pneumococcal diseases (IPDs) and mucosal infections caused by vaccine-specific serotypes have been observed in the targeted population (children aged <5 years). IPD rates have also decreased in adults aged >/=65 years, suggesting the extension of vaccine protection to the unimmunized population. A concomitant decline has been noted in antibiotic-resistant Streptococcus pneumoniae isolates. The incidence of vaccine-serotype IPD varies widely in geographically disparate regions, indicating that serotype coverage alone may not accurately predict the impact of proposed pneumococcal conjugate vaccines with additional serotypes.

    PMID:
    19552985
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk